Paul Arun John, Titus Vijay T K
Orthopaedic Surgeon, Mure Memorial Hospital, Nagpur, 440001 Maharashtra India.
Fellowship in Orthopaedic Oncology, Christian Medical College, Vellore, India.
Indian J Surg Oncol. 2024 Mar;15(Suppl 1):69-75. doi: 10.1007/s13193-023-01763-3. Epub 2023 May 2.
Grade 3 proximal humerus giant cell tumours are uncommon and the results of their surgical management with prosthetic replacement are not well established. We retrospectively studied patients with grade 3 giant cell tumours of proximal humerus treated with excision and prosthetic replacement from January 2009 and December 2018. We identified 13 patients who underwent tumour excision and prosthetic replacement. There were 7 (53.8%) men and 6 (46.2%) women. The mean age at diagnosis was 30.4 years (range 16-48 years). The mean follow-up period was 72.2 months (range 24-132). Margins were positive in 4 (30.8%) patients, ≤ 1 mm in 8 (61.5%) patients, and negative in 1 (7.7%) patient. Local recurrence was seen in 2 (15.4%) patients. 1 out of 2 (50%) patients with local recurrence had pathological fracture at presentation and margins were positive in both (100%) patients. There were 3 (23.1%) complications-1 patient with joint subluxation, 1 patient with fracture post trauma, and 1 patient with surgical site infection. The mean overall Musculoskeletal Tumour Society score was 24 out of 30 (range 21-29). Resection of grade 3 proximal humerus giant cell tumour and reconstruction with prosthesis results in low recurrence rate and good functional outcome and is a valuable treatment option for such tumours.
3级肱骨近端骨巨细胞瘤并不常见,其假体置换手术治疗的效果尚未明确。我们回顾性研究了2009年1月至2018年12月期间接受切除及假体置换治疗的3级肱骨近端骨巨细胞瘤患者。我们确定了13例行肿瘤切除及假体置换的患者。其中男性7例(53.8%),女性6例(46.2%)。诊断时的平均年龄为30.4岁(范围16 - 48岁)。平均随访时间为72.2个月(范围24 - 132个月)。4例(30.8%)患者切缘阳性,8例(61.5%)患者切缘≤1毫米,1例(7.7%)患者切缘阴性。2例(15.4%)患者出现局部复发。2例局部复发患者中有1例(50%)在初诊时发生病理性骨折,且这2例(100%)患者切缘均为阳性。有3例(23.1%)并发症——1例关节半脱位,1例创伤后骨折,1例手术部位感染。肌肉骨骼肿瘤学会的平均总评分在30分中为24分(范围21 - 29分)。切除3级肱骨近端骨巨细胞瘤并用假体重建可导致低复发率和良好的功能结果,是此类肿瘤的一种有价值的治疗选择。